Characterization of Somatic Mutations in Malaysian Luminal Breast Cancer

This case-control study, conducted at the Hospital USM BestARi unit, aimed to identify the serum metabolic fingerprint among individuals with breast lumps and healthy controls, and to discover potential biomarkers. Serum samples from healthy controls, benign breast lump patients, and malignant breast lump patients were analyzed using proton nuclear magnetic resonance spectroscopy (1H NMR). A multivariate data analysis approach was employed, with the OPLS-DA and clustered heat map techniques effectively differentiating between the three groups. The study revealed significant metabolite variations across the groups and proposed D-glucose, glycerol, and glycine as potential biomarkers for breast cancer diagnosis. Metabolic pathways such as alanine, aspartate, glutamate metabolism, and glycine, serine, and threonine metabolism were implicated. The metabolomics approach coupled with multivariate analysis successfully identified key metabolites leading to group separation and suggested altered metabolic pathways. However, further research and integration with other ‘omics’ technologies are necessary for clinical translation.

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Identification of Potential Biomarkers and Metabolic Changes in the Serum of Breast Lump Patients Among Kelantanese Based on 1H NMR Metabolomics

Zulkefly,

Wan Azman,

Omar

et al. 2023

“…These cancer hallmarks are the common traits of tumour cells with their capabilities to alternate the cell growth (sustaining proliferative signalling and evading growth suppressors), to evade apoptosis and cell cycle (resisting cell death and enabling replicative immortality), to modify cellular metabolism (deregulating cellular energetic), to destruct immunological function, to induce angiogenesis, invasion and metastasis. Additionally, the genomic instability [18][19][20][21][22] and inflammation by immune cells facilitate the tumourigenesis [17] .…”

Section: Brief Overview Of Cancermentioning

confidence: 99%

Cancer, Natural Products and Nanodrug Delivery Systems

Ong¹,

Tan²

2020

As an offshoot of nanotechnology, nanomedicine has made great impact in the field of pharmaceutical and biomedical sciences by achieving breakthroughs in therapeutics and diagnostics of diseases in living organisms. One of the promising breakthroughs is the application of natural product-based nanoformulations for the treatment of various human diseases, such as cancer. Principally, the nanoparticle-based drug delivery system (NDDS) aims to overcome the limitations of conventional drug delivery system. NDDS improves the in vivo pharmacological and therapeutic properties of the poorly soluble drugs by dissolving, encapsulating, absorbing and/or attaching the drugs with the matrices of the nanoparticles. The nanoparticles that act as drug reservoirs also aim to control the drug release, enhance the drug uptake by targeted delivery and protect the drug against enzymatic degradation. This review presents a summary of the integration of nanotechnology and phytotherapy to achieve an improved pharmacological response and better clinical outcome in patients undergoing chemotherapy.

“…Improved treatment and early detection have led to a 34% decrease in breast cancer mortality over the past 30 years [7] . Immunohistochemical assessment of estrogen and progesterone receptor protein expression has become a valuable tool for predicting patient outcomes and response to endocrine therapy in breast cancer [8][9][10][11][12] . Another alteration that has received significant attention in the last two decades is amplifying the HER-2/neu gene in human breast cancers.…”

Section: Introductionmentioning

confidence: 99%

A Study Comparing Immunohistochemistry, Fluorescence in situ hybridization, GeneXpert® Breast Cancer STRAT4 Assay for Determining Hormone Receptor, Human Epidermal Growth Factor Receptor 2, Ki67 Status in Invasive Breast Carcinoma in Moroccan women

El Aje,

Naya,

Khoaja

et al. 2023

The accurate assessment of hormone receptors, HER2, and Ki-67 proliferative index provides meaningful information about breast cancer prognosis and prediction of therapy response. Immunohistochemistry, the most common method for evaluating these prognostic biomarkers, can be impacted by numerous variabilities due to pre-analytical/analytical factors and subjective interpretation by pathologists. The Xpert® Breast Cancer STRAT4, an RT-qPCR based system, can be used to classify invasive breast carcinomas based on the assessment of these four biomarkers; Methods: We evaluated ESR1, PGR, ERBB2, and MKi67 mRNA expression by Xpert Breast Cancer STRAT4 and ER, PR, HER2 and Ki67 by IHC (FISH for HER2 IHC 2+) in 200 formalin-fixed paraffin-embedded (FFPE) tissue blocks with invasive breast cancer, collected from the Pathology Department of Casablanca Ibn Rochd University Hospital; Results: Concordance between Xpert ® Breast Cancer STRAT4 and IHC was 93.5% for ER, 83.51% for PR, 95% for HER2 (92% for IHC+FISH), and 81.20% for Ki67 (excluding intermediate IHC Staining 10 ≤ %IHC <20). The simple Kappa coefficient was, for ER, 0.830 (P < 0.0001), 0.565 (P < 0.0001) for PR, 0.838 (P < 0.0001) for HER2-IHC, 0.771 (P < 0.0001) for HER2 IHC+FISH and, for, Ki67, 0.458 (P < 0.0001); Conclusions: We demonstrated globally a high concordance between centrally assessed IHC, IHC+FISH and mRNA measurements of ER/ESR1 and HER2/ERBB2, and a moderate agreement between PR/PGR and Ki67/MKi67. These findings provide an additional, objective, and quantitative assessment of tumor receptor status in breast cancer.